Oncology
Hormone Refractory Prostate Cancer: Increased Progression-Free Survival With Satraplatin and Prednisone
Cora Sternberg
REFERENCE: Abstract 4010, ECCO 14, The European Cancer Conference, Barcelona, 23 – 27 September 2007
CORA STERNBERG, San Camillo and Forlanini Hospital, Rome
Satraplatin could provide a new option for patients with hormone refractory prostate cancer, by giving improved progression-free survival and time to pain progression. Anna Lacey spoke to Cora Sternberg about her group’s results from an international phase III trial, which were announced in Barcelona.
CORA STERNBERG, San Camillo and Forlanini Hospital, Rome
Satraplatin could provide a new option for patients with hormone refractory prostate cancer, by giving improved progression-free survival and time to pain progression. Anna Lacey spoke to Cora Sternberg about her group’s results from an international phase III trial, which were announced in Barcelona.
Peter Ravdin
Significant Drop in US Breast Cancer Incidence Linked to Reduction in Hormone Replacement Therapy
REFERENCE: 2007 Chemotherapy Foundation Symposium
PETER RAVDIN, MD Anderson Cancer Center, Houston
A large registry-based study has provided strong evidence that a significant drop in breast cancer incidence in 2003 was due to the decreased use of hormone replacement therapy. Derek Thorne heard more about the study and its implications when he interviewed Peter Ravdin in New York.
PETER RAVDIN, MD Anderson Cancer Center, Houston
A large registry-based study has provided strong evidence that a significant drop in breast cancer incidence in 2003 was due to the decreased use of hormone replacement therapy. Derek Thorne heard more about the study and its implications when he interviewed Peter Ravdin in New York.
David Vesole
Low-Dose Dexamethasone Better For Newly Diagnosed Multiple Myeloma Treated With Lenalidomide
REFERENCE: 2007 Chemotherapy Foundation Symposium
DAVID VESOLE, St Vincent’s Comprehensive Cancer Center, New York
In newly diagnosed multiple myeloma, lenalidomide plus a lower dose of dexamethasone appears to be favorable for patients, and with a one-year survival rate of 96%, it could be the best result seen in this setting. During the New York symposium Derek Thorne put questions to David Vesole about his findings and their clinical implications.
DAVID VESOLE, St Vincent’s Comprehensive Cancer Center, New York
In newly diagnosed multiple myeloma, lenalidomide plus a lower dose of dexamethasone appears to be favorable for patients, and with a one-year survival rate of 96%, it could be the best result seen in this setting. During the New York symposium Derek Thorne put questions to David Vesole about his findings and their clinical implications.
Daniel DeAngelo
Young Adults With Acute Lymphoblastic Leukemia: Better Success With Pediatric Regimens
REFERENCE: 2007 Chemotherapy Foundation Symposium
DANIEL DEANGELO, Dana-Farber Cancer Institute, Boston
Young adults with ALL may be treated more effectively by using chemotherapy regimens traditionally reserved for children, rather than by using therapies recommended for adults. This came out of a talk in New York given by Daniel DeAngelo, and he later discussed with Peter Goodwin his views and preliminary results from an ongoing trial, including dose-intense asparagine depletion therapy.
DANIEL DEANGELO, Dana-Farber Cancer Institute, Boston
Young adults with ALL may be treated more effectively by using chemotherapy regimens traditionally reserved for children, rather than by using therapies recommended for adults. This came out of a talk in New York given by Daniel DeAngelo, and he later discussed with Peter Goodwin his views and preliminary results from an ongoing trial, including dose-intense asparagine depletion therapy.
To subscribe to the ASCO Audio Journal of Oncology podcast please go to ASCO Audio Journal of Oncology in Advance Presentations or click here.
Download this interviewSimilar Interviews
Health For All 30 Years After Alma Ata? Mental Health And War»
AliaIbrahim Zai, Egbert Sondorp, Gill Walt, Lucy Gilson, Ravi Narayan, Richard Horton, Vikram Patel, Willem Van De Put
Two important symposia have been held in London to discuss healthcare issues posing significant dilemmas to world leaders in the 21st Century. "The Future of Primary Health Care" was attended by public health experts from around the Globe to assess the best options for improving primary health care in the future. It was held on the 30th anniversary of the Alma Ata Declaration made in 1977 which was intended as a blueprint for health provision and identified primary health care as the means through which the global goal of "Health for All" could be achieved. The second meeting, on "Mental Health in Fragile States", was held to raise the profile of mental health care in zones where conflict has taken place or is still happening. Analyses of the key issues and how to deal with them effectively were discussed by top experts from the London School of Hygiene and Tropical Medicine and associated organisations. Peter Goodwin attended both meetings and talked with some of the key speakers.AliaIbrahim Zai, Egbert Sondorp, Gill Walt, Lucy Gilson, Ravi Narayan, Richard Horton, Vikram Patel, Willem Van De Put
LSHTM Audio News: British Association Special Edition»
Astrid Fletcher, Jo Lines, Sari Kovats, Colin Sutherland, Michel Coleman
Peter Goodwin hears from London School of Hygiene and Tropical Medicine experts speaking at the annual science festival of the British Association for the Advancement of Science held in Liverpool, September 6-10, 2008, and from recent scientific publications on: the health impact of global warming, a tropical virus reaching temperate zones, inequalities in cancer outcomes, how eating oily fish can save your eyesight, and free internet publishing scientific journals.Astrid Fletcher, Jo Lines, Sari Kovats, Colin Sutherland, Michel Coleman
© 2008 Audio Medica - Medical Audio News Interviews & Podcasts. 
Post a comment